RxDoctor Payments Data

Jennifer Kerns

Optometrist · Spokane, WANPI 1144228982

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.9%), food and beverage and ownership interests — rather than concentrated in one kind of arrangement. Alcon accounts for 69.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $1,560 and has fallen 98.0% since, to $31 in 2025.

$2,637in general payments, 2019–2025

Across 31 payments — averaging $85.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Bausch & Lomb Americas Inc.$454
  • US Retina LLC$143
  • Coopervision Inc.$90
  • AbbVie$37
  • Johnson & Johnson Vision Care, Inc.$31
  • plus $45 from 2 others
$64,551in research payments, 2019–2025

Across 21 payments — averaging $3073.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$65K

What the payments were for

  • Speaking & faculty fees$1,50057%
  • Food & beverage$99538%
  • Ownership interest$1435%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,637 in reported general payments places this provider in the 85th percentile of 1,267 optometrist providers in Washington.

See all optometrist providers in Washington

Medicare billing

Part B allowed, 2024
$39,474
Medicare patients
209
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine23$21,147
MieboPerfluorohexyloctane/Pf14$13,351
Prednisolone Acetate16$407
Latanoprost37$273
Timolol Maleate20$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$37$21,14723 claims
Bausch & Lomb Americas Inc.Miebo$454$13,35114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,267 optometrist providers in Washington.

Other optometrist in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →